$SIONSionna Therapeutics, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Bayer unpacks plans for $2.2B manufacturing site in Ohio
  Bayer on Friday laid out its vision for a $2.2 billion manufacturing site in Ohio that would create about 600 new jobs in the area. The drugmaker described the site in New Albany as a ...
  endpoints · 2d ago
• Senators grill FDA nominee Heidi Overton
  Heidi Overton’s confirmation hearing to lead the FDA as commissioner concluded after a tense but largely respectful two hours of grilling from Senate HELP Committee members. As expected, questions…
  endpoints · 10d ago
• Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
  Kyverna Therapeutics touted positive one-year results on Thursday in patients with a rare autoimmune disorder called stiff person syndrome. The condition affects about 6,000 patients in the US, cau…
  endpoints · 11d ago
• Pentagon defends designating WuXi AppTec as Chinese military company
  The US Department of Defense is defending its decision to list WuXi AppTec as a Chinese military company, a designation that may restrict the manufacturer's access to government contracts, after a…
  endpoints · 13d ago
• Novo offers low-dose CagriSema data as approval decision looms
  As its capital markets day in London continued on Monday, Novo released data that suggested its investigational metabolic drug CagriSema was competitive with Eli Lilly’s Mounjaro when each was give…
  endpoints · 13d ago
• Iambic signs AbbVie deal, releases next generation of Enchant model
  Iambic Therapeutics released the next generation of one of its main AI models, while signing an R&D partnership with AbbVie. Founded in 2019, the San Diego-based biotech has become a leading startu…
  endpoints · 13d ago
• ADARx targets $319M IPO as TRexBio, Retension join filing queue
  The fall IPO train is boarding. ADARx Pharmaceuticals, a well-funded siRNA biotech in Phase 3, plans to raise about $318 million in its proposed initial public offering, according to its
  endpoints · 13d ago
• Novo aims to diversify with new pipeline assets and bolt-on deals
  Fresh from its rebrand last week, Novo CEO Maziar Mike Doustdar spelled out the strategic vision that goes along with it. At the Danish drugmaker's capital markets day in London on Monday ...
  endpoints · 14d ago
• China sets ambitious goals for global biopharma expansion in new five-year plan
  Any doubts about China’s ambitions as a major global competitor in biopharma are quickly disappearing. On Friday, the Chinese government issued the latest five-year plan for its biotech and pharma…
  endpoints · 16d ago
• Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
  Roche’s T cell engager Lunsumio has passed a Phase 3 trial in a slow-growing type of blood cancer, clearing the path for full approval and a broader label. Lunsumio is a bispecific antibody that ta…
  endpoints · 17d ago